Advanced Therapies: Regulation, Applications and Outlook in the Biotech Sector

Advanced therapies represent one of the most disruptive innovations in modern medicine. They include gene therapy, somatic cell therapy, and tissue engineering, offering new options for treating diseases previously considered incurable through conventional methods.

Their development and application are tightly regulated to ensure safety and efficacy. This article explores the regulatory framework for these therapies in Spain, the impact of the National Advanced Therapies Plan promoted by the Ministry of Health, and their current and future applications in biotechnology.

What Are Advanced Therapies and How Are They Regulated in Spain?

Advanced therapies are medical treatments that use laboratory-modified cells, genes, or tissues to correct, replace, modify, or regenerate damaged structures. They are primarily aimed at treating rare, hereditary, or degenerative conditions that currently lack effective treatment options.

Types of Advanced Therapy Medicinal Products (ATMPs)

ATMPs fall into three main categories:

• Gene therapy: Uses genetic material (DNA or RNA) to regulate, repair, replace, or eliminate faulty genetic sequences.
  
  
• Cell therapy: Involves the substantial manipulation of cells or tissues to alter their biological characteristics, physiological functions, or structural properties.
  
  
• Tissue engineering: Involves manipulated cells or tissues intended to regenerate, restore, or replace damaged human tissue. 

Regulation of Advanced Therapies in Spain

Several legislative frameworks govern the use of advanced therapies in Spain:

• Regulation (EC) No. 1394/2007: Establishes the centralized procedure for marketing authorization of ATMPs at the EU level, coordinated by the European Medicines Agency (EMA).
  
  
• Committee for Advanced Therapies (CAT): Set up by the EMA in 2009 to assess the quality, safety, and efficacy of ATMPs.
  
  
• Royal Decree 477/2014: Governs non-industrial manufacture of ATMPs in Spain, allowing their use in hospital settings under the authorization of the Spanish Agency for Medicines and Medical Devices (AEMPS).
  
  
• Royal Legislative Decree 1/2015: Defines the general principles for authorization and rational use of medicinal products, including ATMPs.

Spain’s Advanced Therapies Plan: Impact and Strategies by the Ministry of Health

The National Plan for Advanced Therapies in the Spanish National Health System (SNS), approved on 15 November 2018, is a major step toward integrating innovative treatments into public healthcare. It focuses on optimizing the use of cutting-edge therapies, particularly CAR-T cell therapies, which have proven effective in complex conditions such as leukemia and lymphoma. The plan responds to growing demand for personalized, precision medicine.

CAR-T therapies are innovative not only in terms of clinical efficacy but also in terms of cost and system impact. Their inclusion in the SNS ensures broad patient access under strict safety and quality standards.

Key Strategies from the Ministry of Health

To ensure equitable and safe implementation of advanced therapies, the Ministry of Health has defined the following strategic areas:

1. Organizational and care model: Specialized centers for CAR-T administration have been established—28 across Spain—meeting the highest quality standards. This ensures coordinated care and personalized treatment.
2. Research and development: The plan promotes public research and the creation of manufacturing hubs within the SNS, improving access and aligning treatments with the latest scientific advances.
3. Expert training: Expert groups are trained to develop protocols based on best practices and to manage adverse effects, ensuring healthcare professionals are well-prepared.
4. Monitoring and continuous improvement: Health indicators and evaluation methods are used to measure the effectiveness of CAR-T therapies. Ongoing data collection and clinical research are key to adapting treatment strategies to evolving patient needs.

Current Applications and Future Outlook of Advanced Therapies in Biotechnology

Advanced therapies are reshaping biotechnology through groundbreaking applications and future potential.

Current Applications

• Cancer: CAR-T cell therapies have proven effective against leukemia and lymphoma and are being explored for other tumor types. Leading Spanish hospitals such as Hospital Universitario La Paz and Hospital Clínic de Barcelona are at the forefront of this field.
  
  
• Genetic disorders: Gene editing technologies like CRISPR-Cas9 are being used to correct mutations in rare diseases such as sickle cell anemia and beta-thalassemia. Adeno-associated viruses are also being used to treat some rare cardiovascular conditions.
  
  
• Metabolic and autoimmune diseases: Cell-based therapies are under investigation for managing metabolic disorders (e.g., type 1 diabetes) and modulating immune responses in autoimmune diseases.
  
  
• Cardiovascular and neurological diseases: Researchers are studying the use of cell therapies to repair tissue after heart attacks and improve outcomes in conditions like multiple sclerosis.
  
  
• Tissue regeneration: Tissue engineering is being used to regenerate cartilage and bone, particularly in joint injuries.

Looking Ahead: The Future of Advanced Therapies

1- Technology and scalability:

• Allogeneic Cell Therapies: Derived from healthy donors, they promise greater scalability and lower production costs compared to autologous therapies.
  
• Advances in gene editing: Techniques such as prime editing and base editing are increasing precision and reducing off-target effects.

2- AI and machine learning:

• These technologies are accelerating target identification and vector optimization, paving the way for more personalized and efficient treatments.

3- New therapeutic areas:

• Advanced therapies are expanding into areas such as cardiovascular disease and neurodegenerative disorders, significantly broadening their therapeutic potential.

Advanced therapies are at the forefront of medical innovation, and at Bexen Bioservices, we specialize in solutions that support their development. We offer a comprehensive range of specialized products to assist biotech and pharma companies, including:

• Ultra-low temperature storage solutions for sensitive biological materials.
  
• Biopreservation media to maintain cell viability in cold or cryogenic conditions.
  
• Products that enhance cellular performance, growth, and functionality.
  
• Integrated solutions for cell processing and storage.
  
  

Discover how we can support your next breakthrough.

References

• Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Preguntas y respuestas sobre terapias avanzadas [Internet]. Madrid: AEMPS; 2020 [cited 04 abril 2025]. Available from: https://www.aemps.gob.es/medicamentos-de-uso-humano/medicamentos-de-fabricacion-no-industrial/preg-resp_ta/
• Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Terapias avanzadas [Internet]. Madrid: AEMPS; 2023  [cited 04 abril 2025]. Available from: https://www.aemps.gob.es/medicamentos-de-uso-humano/medicamentos-de-fabricacion-no-industrial/terapias-avanzadas/
• Agencia Europea de Medicamentos (EMA). Advanced therapy medicinal products: overview [Internet]. Amsterdam: EMA; 2024  [cited 04 abril 2025]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview
• Agencia Europea de Medicamentos (EMA). Comités de la EMA: Comité de Terapias Avanzadas (CAT) [Internet]. Ámsterdam: EMA;  [cited 04 abril 2025]. Available from: https://toolbox.eupati.eu/resources/comites-de-la-ema-comite-de-terapias-avanzadas-cat/?lang=es
• Bayer Hispania SL. Monografías de Farmacia Hospitalaria y de Atención Primaria: Terapias avanzadas (nº 13) [Internet]. Barcelona: Bayer Hispania SL; 2020  [cited 04 abril 2025]. Available from: https://www.sefh.es/bibliotecavirtual/mono13/Monografia_FH_13.pdf?ts=20210219132827
• Biotech Spain. Uso de la biotecnología en terapias avanzadas y nuevas tecnologías en el mercado español [Internet]. 2023  [cited 04 abril 2025]. Available from: https://biotech-spain.com/en/articles/use-of-biotechnology-in-advanced-therapies-and-new-technologies-in-the-spanish-market/
• Comunidad de Madrid. Hospital Ramón y Cajal designado centro CAR-T para uso de terapias avanzadas en tumores hematológicos de población adulta [Internet]. Madrid; 2022  [cited 04 abril 2025]. Available from: https://www.comunidad.madrid/noticias/2022/06/13/hospital-ramon-cajal-designado-centro-car-t-uso-terapias-avanzadas-tumores-hematologicos-poblacion-adulta
• Gobierno de España. La Moncloa. El Gobierno impulsa un plan para potenciar las terapias avanzadas y la fabricación de medicamentos estratégicos en España [Internet]. Madrid: La Moncloa; 2024  [cited 04 abril 2025]. Available from: https://www.lamoncloa.gob.es/serviciosdeprensa/notasprensa/sanidad14/paginas/2024/230924-terapias-avanzadas.aspx
• Gobierno de España. Real Decreto 477/2014, de 13 de junio, por el que se regulan los medicamentos de terapia avanzada [Internet]. Madrid: Boletín Oficial del Estado; 2014  [cited 04 abril 2025]. Available from: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2014-6277
• Haider R, Mehdi A, Geetha Kumari ZA, Zameer S. The Challenges and Future of Advanced Therapies. Clinical Trials and Case Studies. 2023;2(5). doi: 10.31579/2835-835X/037
• Hanna E, Rémuzat C, Auquier P, Toumi, M. Advanced therapy medicinal products: current and future perspectives. J Mark Access Health Policy. 2016 Apr 25;4. doi:10.3402/jmahp.v4.31036
• Institut Universitari Parc Taulí. Global trends in advanced therapies [Internet]. Sabadell; 2023  [cited 04 abril 2025]. Available from: https://www.tauli.cat/en/institut/actualitat/vigilancia-tecnologica/2023/12/tendencias-globales-en-terapias-digitales/
• Lamas-Díaz MJ, Hernández-García C. Terapias avanzadas. Farm Hosp. 2020;44(1):1-2. doi: 10.7399/fh.11373
• Ministerio de Sanidad (España). Terapias avanzadas [Internet]. Madrid: Ministerio de Sanidad;  [cited 04 abril 2025]. Available from: https://www.sanidad.gob.es/areas/farmacia/infoMedicamentos/terapiasAvanzadas/home.htm
• Ministerios de Sanidad, Consumo y Bienestar Social. Plan de Abordaje Terapias Avanzadas en el SNS: Medicamentos CAR [Internet]. Madrid: Gobierno de España; 2018  [cited 04 abril 2025]. Available from: https://www.sanidad.gob.es/areas/farmacia/infoMedicamentos/terapiasAvanzadas/docs/Plan_Abordaje_Terapias_Avanzadas_SNS_15112018.pdf